Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Howard Surks"'
Autor:
Timothy Chow, Pirouz Shamszad, Christopher Vinnard, Esther Yoon, Julia Belinski, Irene Karpenko, Laurent Perrin, Kristen Auwarter, Michael Storek, Howard Surks, Nancy Wong, Yehuda Z. Cohen
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 673-685 (2023)
Abstract SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated disea
Externí odkaz:
https://doaj.org/article/4c9f0415ae8e411dbf130400568bddf6
Autor:
Satish K. Garg, James Thrasher, Karin Wernicke-Panten, Baerbel Rotthaeuser, Howard Surks, Suzanne Pierre, Irene Nowotny
Publikováno v:
Journal of Diabetes Science and Technology
Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55144604e5779947526c56264736cb60
http://europepmc.org/articles/PMC6154226
http://europepmc.org/articles/PMC6154226
Autor:
Gissette Reyes-Soffer, Marianna Pavlyha, Colleen Ngai, Tiffany Thomas, Stephen Holleran, Sekhar Ramakrishnan, Wahida Karmally, Daniel Donovan, Lisa Cowan, William Sasiela, Howard Surks, Jacques Rey, Frank Poitiers, Henry Ginsberg
Publikováno v:
Circulation. 132
Background: Alirocumab is a monoclonal antibody that inhibits binding of PCSK9 to LDL receptors, decreasing their lysosomal degradation and increasing their numbers on cell surfaces. In Phase 2/3 studies, alirocumab 150 mg lowered LDL-cholesterol (C)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::147d4e01647ce5a218090a24a2b09260
https://doi.org/10.1161/circ.132.suppl_3.18390
https://doi.org/10.1161/circ.132.suppl_3.18390